Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational ProgressGlobeNewsWire • 08/05/20
Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/20
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial ResultsGlobeNewsWire • 07/29/20
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/20
Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular TherapiesGlobeNewsWire • 07/14/20
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/11/20
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell TherapyGlobeNewsWire • 05/20/20
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/28/20
Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 04/10/20
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/08/20